Fentanylâœfluanisoneâœmidaz

Total Page:16

File Type:pdf, Size:1020Kb

Fentanylâœfluanisoneâœmidaz REPORTS Fentanyl–fluanisone–midazolam Combination Results in More Stable Hemodynamics than does Urethane–α-chloralose and 2,2,2-tribromoethanol in Mice WILLEKE M.C. JONG, MSC,1 COERT J. ZUURBIER, MSC, PHD,3 ROBBERT J. DE WINTER, MSC, MD, PHD,1* DANYEL A. F. VAN DEN HEUVEL,3 PIETER H. REITSMA, PHD,2 HUGO TEN CATE, MD, PHD,2 AND CAN INCE, PHD3 Near-physiologic hemodynamic conditions for several hours were needed to study cardiovascular physiology in a murine model. We compared two commonly used anesthetic treatments, urethane–α-chloralose (U–αCh; 968 mg U and 65 mg αCh/kg) and 2,2,2- tribromoethanol (TBE; 435 mg/kg) and fentanyl–fluanisone–midazolam (FFM; 3.313 mg fentanyl, 104.8 mg fluanisone, and 52.42 mg midazolam/kg) with respect to mean arterial blood pressure (MAP) and heart rate (HR) for 100 min at similar levels of surgical anesthesia. Assessed every 10 to 15 min, the U–αCh+TBE group maintained a significantly (P < 0.001) lower mean MAP (49 ± 4 mmHg) than did the FFM group (78 ± 5 mmHg). Mean HR in the U–αCh+TBE group significantly (P < 0.001) increased from 308 ± 34 bpm at the beginning to 477 ± 43 bpm at the end of the experiment. In comparison, the FFM group showed a stable HR of 431 ± 37 bpm. The MAP and HR of the U–αCh+TBE group were extremely unstable, with sudden and unpredictable changes in MAP when examined at 1-min intervals. The results of our study show that U–αCh+TBE anesthesia should not be used in murine models in which stable, near-physiologic hemodynamics are needed for cardiovascular studies. The growing availability of genetically altered mice has accel- The opiate fentanyl takes effect rapidly but is relatively short- erated the development of new techniques to study acting. It causes a profound depression of the nervous system, cardiovascular physiology. Measurement of changes in physi- including the respiratory centers in the brain stem, leading to ologic parameters during a cardiovascular intervention study respiratory depression and bradycardia (9, 13). Fluanisone is a requires controlled anesthesia. General anesthesia can be in- neuroleptic of the butyrophenone group. This agent potenti- duced by several volatile, intraperitoneal (i.p.) or intravenous ates the analgesia provided by fentanyl but counteracts its emetic (i.v.) anesthetics. The choice of an anesthetic agent or combina- side effect and partially antagonizes the respiratory depression tion of agents is limited by its side effects, such as cardiac and (9, 13). Midazolam is a benzodiazepine and produces general respiratory depression. Particularly in cardiovascular interven- anesthesia with sufficient muscle relaxation for major surgery tion studies, stable blood pressures and heart rates are crucial. when used in combination with fentanyl and fluanisone. This Anesthetic treatments with urethane (i.e., ethyl carbamate) effect is synergistic (9). If midazolam is used alone, it has a very alone (1-3) or in combination with α-chloralose (4) yield mini- broad safety margin and a short induction time (14). mal cardiovascular and respiratory system depression, and both Advances in the cardiovascular intervention studies in mice at drugs have been advised for use in cardiovascular studies (5, 6). our laboratory prompted the question whether FFM was a good In some countries, however, the use of urethane is prohibited in alternative to using U–αCh+TBE for the reduction of pain in survival studies because of its carcinogenic potential for both anesthetized animals. Here we describe the direct comparison mice and humans (7). After urethane administration, mice fre- of these anesthetic treatments with respect to blood pressure quently develop pulmonary adenomas early in life (7). (BP) and heart rate at similar levels of surgical anesthesia. Supple- The anesthetic 2,2,2-tribromoethanol (TBE) is administered mental doses of anesthetics were administered at signs of a pedal to produce surgical anesthesia (8), with good skeletal muscle withdrawal reflex and a concomitant temporal increase in BP relaxation and only a moderate degree of respiratory depres- even if the mean arterial blood pressure (MAP) was low. Our sion (9). In addition, it is popular now for use in transgenic mice results show that FFM anesthesia is preferable to using U– (10). However, TBE is reported to cause a high rate of post- αCh+TBE for cardiovascular studies in mice. operative fatalities associated with abdominal adhesions, peritonitis, and intestinal disturbances such as diarrhea or even Materials and Methods complete obstruction. These problems are exacerbated when Animals. The Animal Studies Ethics Committee of the Uni- TBE is exposed to light or not used promptly after preparation. versity of Amsterdam approved all experiments. The 13 male Further, TBE must be stored at 4°C (8, 11). SW mice used (Harlan Sprague Dawley, Inc., Horst, The Neth- Flecknell and Mitchell introduced the use of the anesthetic erlands) weighed 25 to 35 g and were housed in open-topped mixture fentanyl–fluanisone–midazolam (FFM) in 1984 (12). cages at constant temperature (21 to 22°C), humidity (50% ± 10%), and light cycle (12:12-h dark:light). Rodent chow (AM-II Department of Cardiology, Cardiovascular Research Institute Amsterdam,1 Laboratory for 10 mm, Hope Farms, Woerden, The Netherlands) and drinking 2 Experimental Internal Medicine, and Department of Anesthesiology, Cardiovascular Re- water were available ad libitum. search Institute Amsterdam,3 Academic Medical Center, University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands Preparation of anesthetic mixtures. To prepare the U–αCh *Corresponding author: Dept. of Cardiology, Room B2-137, Academic Medical Center, mixture, we first dissolved α-chloralose (Sigma, St. Louis, Mo.) University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands in normal saline at 60°C to a final concentration of 10 mg/ml. 28 CONTEMPORARY TOPICS © 2002 by the American Association for Laboratory Animal Science Volume 41, No. 3 / May 2002 We then dissolved urethane (Sigma)by adding the α-chloralose To determine HR, the recorder speed was increased for 2 to 3 solution to a final concentration of 150 mg/ml. sec every 15 min, and the systolic blood pressure peaks were The TBE (Sigma) stock solution was prepared by adding 25 counted. A Y-tube (Y210, Endomed, Didam, The Netherlands) ml 2-methyl-2-butanol (tertiary amyl alcohol; Sigma Aldrich) was inserted directly into the trachea via tracheotomy and con- to a 25-g bottle of dry TBE. A 1:40 dilution in normal saline nected to a small-animal ventilator (CIV101, Columbus resulted in the 2.5% working solution for in vivo use. Congo Instruments, Columbus, Ohio) to ventilate the mouse artificially. red (Sigma) with a transition interval from pH 3.0 (blue) to In light of pilot data (not shown), we decided to ventilate with pH 5.0 (red) was added as an indicator of intact TBE (15), which warmed and humidified air containing 40% O2 at tidal volume was safe for use only as long as the pH had not changed (pH of 0.3 to 0.5 ml, inspiration time/expiration time of 0.25 to 0.30, must be > 5.0). and 100 to 120 breaths per minute. The FFM mixture was prepared by dissolving 1 ml Hypnorm At the end of the experiment, the mice were killed by cervical (Janssen Pharmaceutica, Beerse, Belgium) containing fentanyl dislocation while still anesthetized. and fluanisone and 1 ml Dormicum (Roche, Mijdrecht, The Statistical analysis. In the analysis, we used the averaged MAP Netherlands) containing midazolam in 2 ml sterile water. The tracings for successive 10-min intervals (the “mean MAP”) re- final concentrations were 0.079 mg/ml fentanyl citrate, 2.5 mg/ sulting (together with the MAP at 0 min) in 11 data points per ml fluanisone, and 1.25 mg midazolam/ml (12). mouse during the recording time of 100 min. Study design. The group of seven mice received U–αCh+TBE, To analyze the effect of an anesthetic treatment on the re- and the group of six mice received FFM in random order. peated (averaged) measurements of BP and HR, we set up a (i) Induction. To induce U–αCh anesthesia, each mouse in mixed linear model. Using mixed model methodology, we can that group initially was given 300 mg TBE/kg (15) i.p. A few incorporate the correlation (covariance structure) between dif- minutes later, each received 600 mg U/kg and 40 mg αCh/kg ferent measurements over time from the same animal. We i.p. To induce FFM anesthesia, each mouse received 0.553 mg/ modeled whether measurements close in time are more corre- kg fentanyl citrate, 17.5 mg/kg fluanisone, and 8.75 mg lated than measurements farther apart by imposing a first-order midazolam/kg BW (7 ml FFM/kg) i.p. autoregressive pattern of covariance (18). Time was treated as a (ii) Control and maintenance. A constant infusion of Hartmann continuous variable, and in a sequential analysis, the need for solution (NPBI, Emmer Compascuum, The Netherlands; con- higher-order polynomials of time was examined. centration per liter: 7 g NaCl, 0.4 g KCl, 3.0 g Na lactate, 0.2 g We tested for the effect of treatment and treatment by time CaCl2) or sterile 0.9% saline (Braun, Melsungen, Germany) was interaction. Furthermore, we estimated the differences in mean applied at a rate of 7 ml/kg hourly via the tail vein (9). Extra scores between the groups and identified the 95% confidence boluses of Hartmann solution or pasteurized 4% plasma pro- intervals. P values below 0.05 were considered significant. All tein solution (i.e., gepasteuriseerde proteïne oplossing [GPO]; mixed models were completed by using SAS software version Central Laboratory for Blood Research, Amsterdam, The Neth- 6.12 with the “proc mixed” procedure (19).
Recommended publications
  • The Effects of Antipsychotic Treatment on Metabolic Function: a Systematic Review and Network Meta-Analysis
    The effects of antipsychotic treatment on metabolic function: a systematic review and network meta-analysis Toby Pillinger, Robert McCutcheon, Luke Vano, Katherine Beck, Guy Hindley, Atheeshaan Arumuham, Yuya Mizuno, Sridhar Natesan, Orestis Efthimiou, Andrea Cipriani, Oliver Howes ****PROTOCOL**** Review questions 1. What is the magnitude of metabolic dysregulation (defined as alterations in fasting glucose, total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, and triglyceride levels) and alterations in body weight and body mass index associated with short-term (‘acute’) antipsychotic treatment in individuals with schizophrenia? 2. Does baseline physiology (e.g. body weight) and demographics (e.g. age) of patients predict magnitude of antipsychotic-associated metabolic dysregulation? 3. Are alterations in metabolic parameters over time associated with alterations in degree of psychopathology? 1 Searches We plan to search EMBASE, PsycINFO, and MEDLINE from inception using the following terms: 1 (Acepromazine or Acetophenazine or Amisulpride or Aripiprazole or Asenapine or Benperidol or Blonanserin or Bromperidol or Butaperazine or Carpipramine or Chlorproethazine or Chlorpromazine or Chlorprothixene or Clocapramine or Clopenthixol or Clopentixol or Clothiapine or Clotiapine or Clozapine or Cyamemazine or Cyamepromazine or Dixyrazine or Droperidol or Fluanisone or Flupehenazine or Flupenthixol or Flupentixol or Fluphenazine or Fluspirilen or Fluspirilene or Haloperidol or Iloperidone
    [Show full text]
  • Disposition of T Oxic Drugs and Chemicals
    Disposition of Toxic Drugs and Chemicals in Man, Eleventh Edition Eleventh Edition in Man and Chemicals Drugs Toxic Disposition of The purpose of this work is to present in a single convenient source the current essential information on the disposition of the chemi- cals and drugs most frequently encountered in episodes of human poisoning. The data included relate to the body fluid concentrations of substances in normal or therapeutic situations, concentrations in fluids and tissues in instances of toxicity and the known metabolic fate of these substances in man. Brief mention is made of specific analytical procedures that are applicable to the determination of each substance and its active metabolites in biological specimens. It is expected that such information will be of particular interest and use to toxicologists, pharmacologists, clinical chemists and clinicians who have need either to conduct an analytical search for these materials in specimens of human origin or to interpret 30 Amberwood Parkway analytical data resulting from such a search. Ashland, OH 44805 by Randall C. Baselt, Ph.D. Former Director, Chemical Toxicology Institute Bookmasters Foster City, California HARD BOUND, 7” x 10”, 2500 pp., 2017 ISBN 978-0-692-77499-1 USA Reviewer Comments on the Tenth Edition “...equally useful for clinical scientists and poison information centers and others engaged in practice and research involving drugs.” Y. Caplan, J. Anal. Tox. “...continues to be an invaluable and essential resource for the forensic toxicologist and pathologist.” D. Fuller, SOFT ToxTalk “...has become an essential reference book in many laboratories that deal with clinical or forensic cases of poisoning.” M.
    [Show full text]
  • AVMA Guidelines for the Depopulation of Animals: 2019 Edition
    AVMA Guidelines for the Depopulation of Animals: 2019 Edition Members of the Panel on Animal Depopulation Steven Leary, DVM, DACLAM (Chair); Fidelis Pharmaceuticals, High Ridge, Missouri Raymond Anthony, PhD (Ethicist); University of Alaska Anchorage, Anchorage, Alaska Sharon Gwaltney-Brant, DVM, PhD, DABVT, DABT (Lead, Companion Animals Working Group); Veterinary Information Network, Mahomet, Illinois Samuel Cartner, DVM, PhD, DACLAM (Lead, Laboratory Animals Working Group); University of Alabama at Birmingham, Birmingham, Alabama Renee Dewell, DVM, MS (Lead, Bovine Working Group); Iowa State University, Ames, Iowa Patrick Webb, DVM (Lead, Swine Working Group); National Pork Board, Des Moines, Iowa Paul J. Plummer, DVM, DACVIM-LA (Lead, Small Ruminant Working Group); Iowa State University, Ames, Iowa Donald E. Hoenig, VMD (Lead, Poultry Working Group); American Humane Association, Belfast, Maine William Moyer, DVM, DACVSMR (Lead, Equine Working Group); Texas A&M University College of Veterinary Medicine, Billings, Montana Stephen A. Smith, DVM, PhD (Lead, Aquatics Working Group); Virginia-Maryland College of Veterinary Medicine, Blacksburg, Virginia Andrea Goodnight, DVM (Lead, Zoo and Wildlife Working Group); The Living Desert Zoo and Gardens, Palm Desert, California P. Gary Egrie, VMD (nonvoting observing member); USDA APHIS Veterinary Services, Riverdale, Maryland Axel Wolff, DVM, MS (nonvoting observing member); Office of Laboratory Animal Welfare (OLAW), Bethesda, Maryland AVMA Staff Consultants Cia L. Johnson, DVM, MS, MSc; Director, Animal Welfare Division Emily Patterson-Kane, PhD; Animal Welfare Scientist, Animal Welfare Division The following individuals contributed substantively through their participation in the Panel’s Working Groups, and their assistance is sincerely appreciated. Companion Animals—Yvonne Bellay, DVM, MS; Allan Drusys, DVM, MVPHMgt; William Folger, DVM, MS, DABVP; Stephanie Janeczko, DVM, MS, DABVP, CAWA; Ellie Karlsson, DVM, DACLAM; Michael R.
    [Show full text]
  • Rodenticides Snail Baits
    SPRING/SUMMER 2018 ISSUE 2018 CPD COURSES Key Areas Covered (six hours of CPD) • Case histories for potential poisons cases • Decontamination for poisons cases • Toxicology information resources • Common or tricky poisonings in cats and dogs Cost and Bookings Standard fee: £295 + VAT Early bird fee: £250 + VAT* Each delegate will receive course notes and a CPD certificate (equates to 6 hours CPD training). Lunch and refreshments are provided. Bookings: To reserve a place, please visit the link below and Welcome download the booking form. https://vpisglobal.com/class- Welcome to the Spring/Summer edition of Toxic Times. based-courses-2018/ Date Location Now that we can put thoughts of ice, snow and travel chaos behind us, it’s time to look ahead to the warmer months, which for many, means May 24th Liverpool gardening and for others, dieting. June 8th Winchester In the garden, we’ll discuss slug bait and Our Key Points to Preventing Poisoning July 19th Glasgow how it is vital that it be kept away from is a reminder and aid to keep our pets safe September 13th London pets and we’ll also look at xylitol, the sugar in the home and garden, and although replacement, and how it too must be kept mostly common sense, is worth reiterating. October 18th Exeter securely away from animals. November 29th Birmingham Finally, the regular update of forthcoming The less commonly seen rodenticide, CPD courses, which this year are proving alphachloralose is also discussed. extremely popular- possibly due in part * Early bird discount applies to bookings made up to 8 weeks prior to the course Case Corner highlights some recent to the provision of homemade cakes.
    [Show full text]
  • Alphachloralose Product-Type 14 (Rodenticide)
    CA-May08-Doc.3.1a WORKING DOCUMENT: DOES NOT NECESSARILY REPRESENT THE VIEWS OF THE COMMISSION Directive 98/8/EC concerning the placing biocidal products on the market Inclusion of active substances in Annex I or IA to Directive 98/8/EC Assessment Report Alphachloralose Product-type 14 (rodenticide) 30 May 2008 Annex I - PT Alphachloralose (PT 14) Assessment report Finalised in the Standing Committee on Biocidal Products at its meeting on 30 May 2008 in view of its inclusion in Annex I to Directive 98/8/EC CONTENTS 1. STATEMENT OF SUBJECT MATTER AND PURPOSE .................................. 4 1.1. Procedure followed.......................................................................................... 4 1.2. Purpose of the assessment report...................................................................5 1.3. Overall conclusion in the context of Directive 98/8/EC ...............................5 2. OVERALL SUMMARY AND CONCLUSIONS...................................................6 2.1. Presentation of the Active Substance ............................................................6 2.1.1. Identity, Physico-Chemical Properties & Methods of Analysis.......6 2.1.2. Intended Uses and Efficacy ...............................................................7 2.1.3. Classification and Labelling ..............................................................8 2.2. Summary of the Risk Assessment................................................................10 2.2.1. Human Health Risk Assessment......................................................10
    [Show full text]
  • Prohibited Substances List
    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
    [Show full text]
  • Curable Composition and Skin Adhesive
    (19) TZZ ¥Z¥_T (11) EP 2 957 303 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 23.12.2015 Bulletin 2015/52 A61L 15/58 (2006.01) A61L 24/04 (2006.01) C08K 5/10 (2006.01) C09J 167/06 (2006.01) (2006.01) (21) Application number: 14173247.9 C08L 67/06 (22) Date of filing: 20.06.2014 (84) Designated Contracting States: (72) Inventor: Schüwer, Nicolas AL AT BE BG CH CY CZ DE DK EE ES FI FR GB 1010 Lausanne (CH) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR (74) Representative: Hoffmann Eitle Designated Extension States: Patent- und Rechtsanwälte PartmbB BA ME Arabellastraße 30 81925 München (DE) (71) Applicant: NITTO DENKO CORPORATION Osaka 567 (JP) (54) Curable composition and skin adhesive (57) The present invention pertains to compositions The composition of the invention may be cross- linked to containing a polycondensate and optionally an oil com- yield an adhesive composition. The composition of the ponent, wherein the polycondensate is derived from a invention and the adhesive composition of the invention dicarboxylic acid component, a diol component and an may be used on substrates such as tapes and patches ethylenically unsaturated dicarboxylic acid component. in the medical field. EP 2 957 303 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 957 303 A1 Description 1. Technical Field of the Invention 5 [0001] The present invention relates to a curable composition comprising: a polycondensate of a dicarboxylic acid, a diol, and a polymerizable ethylenic derivative; and optionally an oil additive.
    [Show full text]
  • Anesthesia and Analgesia in Laboratory Animals
    GUIDELINES ON ANESTHESIA AND ANALGESIA IN LABORATORY ANIMALS University of South Florida provides the following guidelines for use by IACUC-certified faculty and staff. CONTENTS PAGE A. Background……………………………………………………….…………………………… 1 B. Definitions....……………………………………………………..…………………………….. 2 C. General Considerations……………………………………….,…………………………….. 3 D. Controlled Substances……………………………………….……………………………… 3 E. Pre-Anesthetic Treatments………………………………….………………………………. 4 F. General Anesthetics………………………………………….………………………………. 4 G. Neuromuscular Blocking Agents………………………….……………………………….. 5 H. Monitoring Anesthesia…………………………………….…………………………………. 6 I. Analgesics……………………………………………………………………………………… 7 J. Comments regarding Anesthetics and Analgesics……………………………………... 7 REFERENCE TABLES PAGE I. Signs of Pain and Distress in Laboratory Animals………………………………………… 10 II. Commonly Used Anesthetics and Analgesics for Mice….………..…...….………...…… 11 III. Commonly Used Anesthetics and Analgesics for Rats……………………………...…… 12 IV. Commonly Used Anesthetics and Analgesics for Gerbils……….……………..…….. 13 V. Commonly Used Anesthetics and Analgesics for Hamsters…….……………..……. 14 VI. Commonly Used Anesthetics and Analgesics for Guinea Pigs….…………….….……. 15 VII. Commonly Used Anesthetics and Analgesics for Rabbits.……...…………….………… 16 VIII. Commonly Used Anesthetics and Analgesics for Dogs.…………………….…………… 17 IX. Commonly Used Anesthetics and Analgesics for Cats.……………………..…………… 18 X. Commonly Used Anesthetics and Analgesics for Pigs ..……………..….………………..19 XI. Commonly Used Anesthetics and Analgesics
    [Show full text]
  • Veterinary Anesthetic and Analgesic Formulary 3Rd Edition, Version G
    Veterinary Anesthetic and Analgesic Formulary 3rd Edition, Version G I. Introduction and Use of the UC‐Denver Veterinary Formulary II. Anesthetic and Analgesic Considerations III. Species Specific Veterinary Formulary 1. Mouse 2. Rat 3. Neonatal Rodent 4. Guinea Pig 5. Chinchilla 6. Gerbil 7. Rabbit 8. Dog 9. Pig 10. Sheep 11. Non‐Pharmaceutical Grade Anesthetics IV. References I. Introduction and Use of the UC‐Denver Formulary Basic Definitions: Anesthesia: central nervous system depression that provides amnesia, unconsciousness and immobility in response to a painful stimulation. Drugs that produce anesthesia may or may not provide analgesia (1, 2). Analgesia: The absence of pain in response to stimulation that would normally be painful. An analgesic drug can provide analgesia by acting at the level of the central nervous system or at the site of inflammation to diminish or block pain signals (1, 2). Sedation: A state of mental calmness, decreased response to environmental stimuli, and muscle relaxation. This state is characterized by suppression of spontaneous movement with maintenance of spinal reflexes (1). Animal anesthesia and analgesia are crucial components of an animal use protocol. This document is provided to aid in the design of an anesthetic and analgesic plan to prevent animal pain whenever possible. However, this document should not be perceived to replace consultation with the university’s veterinary staff. As required by law, the veterinary staff should be consulted to assist in the planning of procedures where anesthetics and analgesics will be used to avoid or minimize discomfort, distress and pain in animals (3, 4). Prior to administration, all use of anesthetics and analgesic are to be approved by the Institutional Animal Care and Use Committee (IACUC).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Chloral Hydrate
    NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDY OF CHLORAL HYDRATE (AD LIBITUM AND DIETARY CONTROLLED) (CAS NO. 302-17-0) IN MALE B6C3F1 MICE (GAVAGE STUDY) NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 December 2002 NTP TR 503 NIH Publication No. 03-4437 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S. Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health; the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control and Prevention. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agencies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Technical Report were performed under the direction of the NCTR and were conducted in compliance with NTP laboratory health and safety requirements and must meet or exceed all applicable federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals.
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]